Table 1 Characteristics of patients (n = 682)
From: Cardiovascular disease events within 5 years after a diagnosis of breast cancer
All patients | |
|---|---|
Patients (n) | 682 |
Clinical characteristics | |
Gender (female) | 676 (99.12%) |
Age (mean years) | 62.5 (50.9–72.6) |
Body weight (mean kg ± SD) | 66.3 ± 13.6 |
Body Mass Index (n = 662) (mean kg/m2 ± SD) | 25.5 ± 5.0 |
Obesity | 107 (15.7%) |
Cancer characteristics | |
Breast side (left) | 357 (52.3%) |
UICC Breast Staging | |
O | 39 (0.7%) |
I | 327 (47.9%) |
II | 226 (33.1%) |
III | 75 (11.0%) |
IV | 15 (2.2%) |
Histological type | |
Infiltrating Ductal Carcinoma | 547 (80.2%) |
Infiltrating Lobular Carcinoma | 74 (10.9%) |
Carcinoma in situ | 39 (5.7%) |
Histopronostic criteria | |
Her2 positive | 78 (11.4%) |
Hormonal receptors positives | 565 (82.8%) |
Triple negative | 58 (8.5%) |
SBR 1–2 grade | 454 (66.6%) |
SBR 3 grade | 191 (28.0%) |
Cancer treatments | |
Surgery | 665 (97.5%) |
Chemotherapy | 256 (37.5%) |
Trastuzumab therapy | 60 (8.8%) |
Radiotherapy | 673 (98.7%) |
Hormone blocking therapy | 551 (80.8%) |
Cardiovascular characterics | |
Cardiovascular risk factors | 340 (49.9%) |
Hypertension | 251 (73.8%) |
Diabetes mellitus | 59 (17.4%) |
Smoking (current or stopped less than 2 years) | 53 (15.6%) |
Hypercholesterolemia | 119 (35%) |
Atrial fibrillation (AF) at cancer diagnosis | 22 (3.2%) |
Cardiovascular treatments at cancer diagnosis | 214 (31.4%) |
Β-blockers | 71 (10.4%) |
ACE inhibitor or AIIRAs | 100 (14.7%) |
CCB | 63 (9.2%) |
Diuretics | 69 (10.1%) |
Anticoagulant | 20 (2.9%) |
One antiplatelet | 40 (5.9%) |
Dual antiplatelets | 3 (0.43%) |